12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iclusig ponatinib regulatory update

FDA granted accelerated approval to Iclusig ponatinib from Ariad to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) that is resistant or intolerant to prior treatment with tyrosine kinase inhibitors (TKIs). The approval comes more than 3 months ahead of the March 27, 2013, PDUFA date. Iclusig's label includes a black box warning...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >